FUT8 (alpha-1,6-fucosyltransferase)

FUT8 is the sole human core α1,6-fucosyltransferase, adding GDP-fucose in α1,6 linkage to the innermost GlcNAc of N-glycans. Approximately 90–95% of serum IgG carries core fucose. The small defucosylated fraction (~5–10%) has dramatically enhanced binding to FcγRIIIA (CD16) — up to 50-fold tighter (see igg-fc-glycosylation) — making FUT8 the primary engineering lever for next-generation therapeutic antibodies. For aging biology, FUT8 is less central than b4galt1 or st6gal1: core fucosylation does not show the strong age-associated trajectory of galactosylation or sialylation, and the aging relevance is modest. FUT8’s principal importance here is as the biochemical competitor of mgat3-mediated bisecting GlcNAc addition.

Identity

UniProt: Q9BYC5 (FUT8_HUMAN) — confirmed via UniProt REST API 2026-05-20
NCBI Gene: 2530
HGNC: 4019
Ensembl: ENSG00000033170
Mouse ortholog: Fut8
Length: 575 amino acids (canonical isoform; longest of the FUT family)
EC number: 2.4.1.68

Enzymology

FUT8 is a type II single-pass transmembrane glycoprotein resident in the Golgi apparatus (trans cisternae). It catalyzes:

GDP-Fuc + GlcNAc(β1,4-GlcNAc-Asn) → Fuc(α1,6)-GlcNAc(β1,4-GlcNAc-Asn) + GDP

The acceptor is the core GlcNAc directly linked to Asn; the sugar transferred (L-fucose from GDP-Fuc) is added in α1,6 linkage. This is the core fucosylation reaction — distinguishable from antennary or Lewis-type fucosylation by other FUT enzymes.

Structural constraint — mutual exclusion with bisecting GlcNAc: MGAT3-mediated addition of bisecting GlcNAc to the central mannose creates a steric block that prevents FUT8 from accessing its substrate. As a consequence, individual IgG Fc glycoforms are either core-fucosylated or bisected, but not both ¹. This mutual exclusion is the mechanistic basis for the inverse relationship between G0F/G1F/G2F and G0FB/G1FB/G2FB glycoform pairs observed in IgG glycome profiling.

GDP-fucose substrate supply: FUT8 requires GDP-fucose as the activated sugar donor. GDP-fucose biosynthesis occurs via two pathways: (i) the de novo pathway from GDP-mannose; (ii) the salvage pathway from free fucose. Disruption of GDP-fucose biosynthesis (as in Lec13 CHO cells) also produces afucosylated IgG, providing an alternative engineering route to FUT8 knockout ¹.

Position in the IgG Fc glycosylation cascade

FUT8 acts at an early branch point in the Golgi processing cascade, competing with MGAT3:

Step	Enzyme	Product
1–2	MGAT1, MGAT2	Biantennary complex-type scaffold
3a	fut8	Core fucosylation → G0F scaffold
3b	mgat3	Bisecting GlcNAc → blocks FUT8 (mutually exclusive)
4	b4galt1	Galactosylation
5	st6gal1	Sialylation

Aging relevance — modest

Core fucosylation of IgG is relatively stable with age compared to galactosylation and sialylation. The dominant age-associated glycome changes (G0 rise, G2 fall, sialylation loss) are driven by b4galt1 and st6gal1 decline, not FUT8. Some studies have noted a slight increase in defucosylation with age, but this is small compared to the galactosylation signal and not consistently replicated ²³. FUT8 has no direct connection to estrogen signaling or the inflammaging feedback loop (which primarily operates through B4GALT1/ST6GAL1). For these reasons, FUT8 has an empty hallmarks: list and no link to chronic-inflammation.

The GWAS literature (Wahl 2018, Landini 2022) does identify FUT8 as a locus for IgG fucosylation variation ⁴⁵, confirming its role in genetic control of IgG fucosylation — but this is a distinct biological question from aging trajectories.

Therapeutic antibody engineering — the central FUT8 application

FUT8’s primary clinical relevance is as the engineering target for afucosylated (defucosylated) therapeutic monoclonal antibodies. Core fucose on IgG sterically hinders FcγRIIIA binding; removing it yields dramatically enhanced ADCC via NK cells and macrophages ¹.

Yamane-Ohnuki et al. 2004 established the FUT8 KO CHO cell line platform (POTELLIGENT):

Both FUT8 alleles were disrupted in CHO/DG44 cells
Anti-CD20 IgG1 produced in these cells showed ~100-fold enhanced ADCC vs the reference drug Rituxan (rituximab)
Antigen binding and CDC (complement-dependent cytotoxicity) were unchanged ⁶

This work became the basis for commercially deployed defucosylated therapeutic antibodies:

Drug	Target	Indication	Approval
Obinutuzumab (Gazyva)	CD20	CLL, follicular lymphoma	FDA 2013
Mogamulizumab (Poteligeo)	CCR4	CTCL, ATLL	FDA 2018 (Japan 2012)

Additional defucosylated antibodies are in clinical development. Multiple CHO-cell engineering platforms (POTELLIGENT; GlymaxX) enable commercial production.

ADCC enhancement magnitude varies by the FcγRIIIA polymorphism (Phe158 vs Val158 allele): both alleles benefit substantially, with the lower-affinity Phe158 allele showing a larger relative improvement ¹. The ~50-fold enhancement figure (from Shields 2002, Hu4D5 antibody assay) and the ~100-fold figure (from Yamane-Ohnuki 2004, anti-CD20 ADCC) reflect different antibodies and assay conditions — both are confirmed in their respective publications.

Knockout phenotype (mouse)

Fut8-deficient mice (Wang et al. 2005, PNAS) exhibit:

Severe growth retardation and early postnatal death — approximately 70% of knockout pups die within the first 3 days of birth; surviving pups show severe growth retardation ⁷
Emphysema-like lung pathology — alveolar structural abnormality resembling emphysema
Elevated matrix metalloproteinases (MMP-12, MMP-13) and reduced elastin in lung
Impaired TGF-β1 receptor signaling (reduced Smad2 phosphorylation) — exogenous TGF-β1 partially rescues the lung phenotype, demonstrating that core fucosylation of TGF-β receptors is required for their normal signaling ⁷

Strain background: Wang 2005 used 129SvJ ES cells crossed with B6C3F1 blastocysts (C57BL/6 × C3H F1 hybrid background); the phenotypic severity may differ in a congenic pure C57BL/6 background.

Implication for therapeutic FUT8 inhibition: The Fut8 KO phenotype demonstrates that systemic FUT8 inhibition is toxic in mice — multiple glycoprotein substrates (TGF-β receptors, EGFR, integrins, E-cadherin) require core fucosylation for normal function. This renders chronic systemic FUT8 inhibition an unacceptable therapeutic strategy for aging or anti-inflammatory indications. Clinical strategies therefore focus exclusively on cell-line engineering (FUT8-KO CHO cells for mAb production), not in vivo FUT8 inhibition.

Additionally, congenital FUT8 deficiency in humans (CDGF1 — congenital disorder of glycosylation with defective fucosylation 1) causes severe clinical phenotype: poor growth, hypotonia, skeletal anomalies, developmental delay, and intellectual disability, consistent with the mouse KO data.

Pharmacological inhibitors

Research-stage FUT8 inhibitors include:

2-fluorofucose (2-F-Fuc) — a GDP-fucose analog that is incorporated into glycans, preventing subsequent FUT8 substrate recognition; used experimentally to produce defucosylated IgG in cell culture; not approved or in clinical trials for systemic use ⁸
Competitive GDP-fucose analogs under development; no clinical-stage agent as of 2026-05-20

Druggability tier is set to 2 (high-quality research probe; clinical cell-line engineering for mAb production is well-established; no systemic FUT8 inhibitor in clinical development for aging or inflammatory indication).

Substrate breadth beyond IgG

FUT8 fucosylates many N-glycoprotein substrates: TGF-β receptors, EGF receptor, integrins, E-cadherin, fibronectin receptors, B7H3 (an immune checkpoint ligand on cancer cells ⁸). The broad substrate scope makes systemic FUT8 inhibition biologically complex and clinically hazardous, as noted above.

Limitations and gaps

Core fucosylation is not a primary aging-relevant IgG glycome signal; FUT8 has minimal relevance to the GlycanAge clock.
FUT8 global inhibition is toxic per KO phenotype; no systemic FUT8 inhibitor is in development for aging-context indications.
The mechanism by which FUT8 and MGAT3 compete for the same glycan substrate (mutual exclusion) is established structurally but the in vivo determinants of the FUT8 vs MGAT3 balance in B cells across age have not been characterized. needs-replication
No GWAS or Mendelian randomization study has tested whether FUT8-locus variants predict aging outcomes (independent of IgG fucosylation patterns). mr-causal-evidence is therefore not-tested.

Footnotes

doi:10.1074/jbc.m202069200 · in-vitro (Lec13 CHO cells + primary IgG binding/ADCC assays) · Shields RL, Lai J, Keck R et al., Presta LG · J Biol Chem 277:26733–26740 (2002) · fucose-deficient IgG1 binds FcγRIIIA up to 50-fold more tightly (EC50 0.07–0.24 µg/ml vs >10 µg/ml); ~50-fold ADCC enhancement in NK cell assays; FUT8 / GDP-fucose as mechanistic basis; bisecting GlcNAc (MGAT3) and core fucosylation mutual exclusion context · archive: downloaded ↩ ↩² ↩³ ↩⁴
doi:10.1016/j.cellimm.2018.07.009 · PMID 30107893 · review · Gudelj I, Lauc G, Pezer M · Cell Immunol 2018 · IgG glycome in aging; core fucosylation relatively age-stable context · archive: download failed no-fulltext-access ↩
doi:10.1371/journal.pone.0012566 · PMID 20830288 · observational (n=1,967; Leiden Longevity Study — 1,287 offspring + 680 partners of nonagenarian sibling pairs) · Ruhaak LR, Uh HW, Beekman M et al. · PLoS One 5:e12566 (2010) · decreased bisecting GlcNAc IgG glycoforms associated with longevity in under-60 participants; galactosylation decreases with age; age-related bisecting GlcNAc increase in galactosylated glycoforms; core fucosylation age-trajectory context · archive: downloaded ↩
doi:10.3389/fimmu.2018.00277 · PMID 29535710 · GWAS (~1,800 subjects) · Wahl A, van den Akker E, Klaric L et al., Gieger C · Front Immunol 9:277 (2018) · replicated GWAS signals for IgG glycan variation at FUT8, ST6GAL1, B4GALT1, MGAT3 · archive: status pending ↩
doi:10.1038/s41467-022-29189-5 · PMID 35332118 · GWAS (n=2,020) · Landini A, Trbojević-Akmačić I, Wilson JF, Klarić L et al. · Nat Commun 2022 · FUT8 and FUT6 are shared IgG-and-transferrin glycan GWAS loci; B4GALT1, ST6GAL1, MGAT3 are IgG-specific · archive: downloaded ↩
doi:10.1002/bit.20151 · PMID 15352059 · in-vitro/biotech (FUT8 KO CHO cell development) · Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M et al., Satoh M · Biotechnol Bioeng 87:614–622 (2004) · FUT8 KO CHO cells produce completely defucosylated antibodies; anti-CD20 IgG1 shows ~100-fold enhanced ADCC vs Rituxan; POTELLIGENT platform basis · archive: not_oa ↩
doi:10.1073/pnas.0507375102 · PMID 16236725 · in-vivo (Fut8 KO mouse; 129SvJ × B6C3F1 background) · Wang X et al., Taniguchi N · Proc Natl Acad Sci USA 102:15791–15796 (2005) · ~70% of Fut8-/- pups die within the first 3 days of birth; survivors show severe growth retardation + emphysema-like lung changes; TGF-β1 receptor signaling impaired (reduced Smad2 phosphorylation); MMP-12/13 elevated; exogenous TGF-β1 partially rescues lung phenotype; core fucosylation required for TGF-β receptor function · archive: downloaded ↩ ↩²
doi:10.1038/s41467-021-22618-x · PMID 33976130 · in-vitro/in-vivo (triple-negative breast cancer models) · Huang Y, Deng R et al. · Nat Commun 12:2672 (2021) · FUT8 fucosylates B7H3 (immune checkpoint ligand); FUT8 knockdown + 2-fluorofucose inhibitor studied; 2-F-Fuc + anti-PDL1 combinatorial activity; cancer-biology context, not aging context · archive: pending ↩ ↩²

🧬 Aging Wiki

Explorer

fut8